Cogent Biosciences submitted a new drug application (NDA) to the U.S. FDA for bezuclastinib to treat advanced systemic mastocytosis. The FDA submission is a positive regulatory milestone that can support future approvals, though near-term outcomes depend on the review timeline and results.
Cogent Biosciences submitted a new drug application (NDA) to the U.S. FDA for bezuclastinib to treat advanced systemic mastocytosis. The FDA submission is a positive regulatory milestone that can support future approvals, though near-term outcomes depend on the review timeline and results.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
